Bit & Bridle

Equine Xylazine Toxicity

Other Names

  • Rompun Toxicity (Rompun is a common brand name for xylazine)
  • Sedazine Overdose
  • Alpha-2 Agonist Toxicity
  • Xylazine Overdose in Horses

What Is Xylazine Toxicity in Horses?

Xylazine is an alpha-2 adrenergic agonist widely used in veterinary medicine as a sedative, analgesic, and muscle relaxant in horses. It is one of the most commonly administered drugs in equine practice, used for procedures ranging from wound management to pre-anaesthetic preparation. At appropriate therapeutic doses, xylazine provides reliable, titratable sedation. However, when administered in excess — whether through dosing error, route confusion, individual hypersensitivity, or accidental exposure — xylazine can produce life-threatening toxicity.

Horses are notably more sensitive to xylazine than many other species. The sedative effect in horses occurs at doses far lower than those required in, for example, cattle or dogs. This pharmacological sensitivity means that errors in dose calculation or route of administration can quickly produce clinical signs of overdose, even in experienced hands.

Toxicity can occur in field situations when well-intentioned owners or untrained individuals administer xylazine without veterinary supervision, when a horse receives a calculated dose but reacts unusually, or when pharmaceutical xylazine is used outside the context for which it was prescribed. Understanding the signs of overdose and the appropriate response is important for anyone working with or caring for horses.

Causes

Xylazine toxicity arises when plasma concentrations of the drug exceed the therapeutic range. Common precipitating causes include:

  • Overdose: Administration of a dose above the recommended range for the intended route. Intravenous xylazine acts rapidly and at lower doses than intramuscular xylazine; inadvertent IV administration of a dose calculated for IM use is a recognised cause of toxicity.
  • Accidental intravenous injection: Xylazine intended for intramuscular injection but inadvertently delivered intravenously produces a significantly more rapid and intense response, potentially reaching toxic levels.
  • Use without veterinary supervision: Administration by untrained individuals who misjudge dose or route.
  • Individual hypersensitivity: Some horses have exaggerated responses to standard doses due to individual variation in receptor density or drug metabolism.
  • Concurrent medications: Other CNS depressants (opioids, acepromazine, detomidine) used concurrently potentiate xylazine’s effects and can precipitate overdose-like clinical signs at otherwise acceptable individual doses.
  • Underlying illness: Horses that are debilitated, hypovolaemic, or in severe pain may have altered drug responses and be more sensitive to standard doses.

Symptoms and Signs

The clinical signs of xylazine toxicity reflect the drug’s pharmacological actions — profoundly amplified. Mild-to-moderate overdose produces:

  • Extreme sedation — the horse may be unable to stand or maintain sternal recumbency
  • Marked head droop and ptosis (drooping eyelids)
  • Significant ataxia and muscle weakness
  • Reduced response to stimuli
  • Bradycardia (abnormally slow heart rate) and cardiac arrhythmias
  • Respiratory depression — slow, shallow breathing
  • Hypotension (low blood pressure)
  • Hypersalivation or dry mouth depending on dose
  • Reduced gut motility — risk of ileus

In severe overdose, signs escalate to:

  • Recumbency — the horse is unable to rise
  • Marked respiratory depression progressing to respiratory arrest
  • Cardiovascular collapse
  • Cyanosis (blue discolouration of mucous membranes)
  • Hypothermia
  • Seizures in some cases
  • Death if untreated

A critical secondary risk in recumbent horses is myopathy (post-anaesthetic muscle damage) from prolonged recumbency, as well as aspiration pneumonia if the horse vomits or if secretions are not managed. Horses should never be left unattended whilst under xylazine sedation.

Diagnosis

Diagnosis of xylazine toxicity is primarily clinical and based on history and physical examination findings:

  • Exposure history: Confirmation that xylazine was administered, along with the dose, route, and timing relative to onset of clinical signs, is the cornerstone of diagnosis.
  • Clinical signs: The rapid onset of profound sedation, bradycardia, respiratory depression, and hypotension in the context of xylazine administration points clearly to overdose or adverse response.
  • Cardiovascular monitoring: ECG may reveal arrhythmias (most commonly first- or second-degree atrioventricular block), which are consistent with xylazine effect.
  • Blood pressure monitoring: Initial hypertension followed by hypotension is the classic haemodynamic pattern.
  • Pulse oximetry: Monitors oxygen saturation and alerts to respiratory depression.
  • Blood gas analysis: Elevated carbon dioxide and reduced oxygen saturation confirm respiratory compromise in severe cases.

Laboratory drug confirmation is rarely available in the field and is generally not necessary for management decisions given the clear clinical picture.

Treatment

Management of xylazine toxicity is primarily supportive, with the specific antidote atipamezole available to reverse the effects directly:

  • Atipamezole (Antisedan): This alpha-2 antagonist reverses xylazine’s sedative and cardiovascular effects rapidly. It is the treatment of choice in cases of significant overdose. The dose and route must be carefully calculated — rapid or excessive reversal can cause excitability and abrupt arousal, which carries its own risks in a recumbent horse.
  • Yohimbine: Another alpha-2 antagonist that can be used to partially reverse xylazine effects, particularly useful in field situations.
  • Respiratory support: In cases of respiratory depression, supplemental oxygen should be provided. In severe cases with respiratory arrest, assisted ventilation via nasotracheal intubation may be necessary.
  • Cardiovascular monitoring and support: Intravenous fluids may be required to support blood pressure. Atropine may be used for severe bradycardia unresponsive to reversal agents.
  • Positioning: Recumbent horses should be positioned carefully in lateral recumbency to protect the airway and minimise pressure-related myopathy. Padding of limbs is important during prolonged recumbency.
  • Temperature management: Monitor for hypothermia and provide blankets or heat support as needed.

Recovery is generally complete with appropriate treatment. The British Equine Veterinary Association (BEVA) recommends that xylazine and other sedatives should only be administered under veterinary supervision to ensure appropriate patient monitoring and access to reversal agents.

Prevention

Most cases of xylazine toxicity are preventable:

  • Xylazine should only be administered by or under the direct supervision of a veterinary surgeon who has assessed the horse and confirmed an appropriate dose and route.
  • Always confirm the intended route before administration — IV and IM doses differ significantly.
  • Never administer xylazine to a horse without a reversal agent (atipamezole or yohimbine) accessible on site.
  • Monitor all sedated horses continuously until they are fully recovered and standing safely.
  • Store xylazine securely and ensure only trained personnel have access.
  • When combining sedative or analgesic agents, reduce individual drug doses appropriately to account for additive or synergistic effects — always follow veterinary guidance on combination protocols.

Prognosis

Prognosis for xylazine toxicity is generally good when the condition is recognised promptly and appropriate treatment is administered. Mild to moderate overdose, managed with supportive care and reversal agents, typically resolves without lasting consequences. Severe overdose with prolonged recumbency carries greater risk of secondary complications including pressure myopathy, aspiration pneumonia, and post-anaesthetic neuropathy. Deaths from xylazine toxicity, whilst uncommon, do occur — most often in cases where the horse was left unmonitored or where reversal agents were not available. Rapid response is the key determinant of outcome.

When to Call the Vet

Contact your veterinary surgeon immediately if:

  • A horse has received xylazine and shows signs of extreme sedation beyond what was expected for the dose given
  • The horse is unable to stand, is recumbent, or appears to be struggling to breathe
  • Heart rate is abnormally slow or irregular following xylazine administration
  • A horse has been accidentally exposed to xylazine (e.g., via a needlestick incident or ingestion)
  • There is any uncertainty about the dose or route of administration given

This is a veterinary emergency. Do not wait to see if signs resolve on their own. See our guide on equine sedation terminology for more on how alpha-2 agonists work in horses.

Frequently Asked Questions

Is xylazine safe to use at home without a vet?

No. Xylazine should only be administered under veterinary supervision. The margin between a sedative dose and a toxic dose is narrow, the drug must be titrated to the individual horse, and a reversal agent must be immediately available. Using xylazine without a vet on-site — regardless of the owner’s experience — carries significant risk of serious harm to the horse.

How fast does xylazine toxicity develop?

When administered intravenously, the sedative effects of xylazine begin within 1–2 minutes and peak within 3–5 minutes. Overdose signs can therefore develop very rapidly following IV injection. Intramuscular injection has a slower onset — typically 10–15 minutes — which provides slightly more time to intervene, but does not eliminate the risk of toxicity.

What is the reversal agent for xylazine?

Atipamezole (brand name Antisedan) is the primary reversal agent for xylazine and other alpha-2 agonists. Yohimbine is an alternative. Both work by competitively blocking alpha-2 adrenergic receptors, rapidly reversing sedation and cardiovascular depression. Your vet will administer these at the appropriate dose — reversal must be carefully managed to avoid adverse reactions from too-rapid arousal.

Can xylazine affect humans?

Yes. Accidental needlestick injuries involving xylazine can cause sedation, low blood pressure, and bradycardia in humans. Anyone accidentally injected with xylazine should seek immediate medical attention. Inform emergency medical personnel that the substance involved is xylazine, an alpha-2 agonist, for which the reversal agent atipamezole may be required.